New drug cocktail aims to boost transplant success in elderly leukemia patients
NCT ID NCT07563920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant can help older adults with acute myeloid leukemia stay in remission longer. About 93 patients aged 55 to 75 who are in their first remission will receive the treatment and be followed for at least a year. The goal is to see if this approach reduces relapse and improves survival, while managing side effects like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thiotepa, busulfan, and fludarabine (TBF) chemotherapy
What this could lead to
If successful, this approach could offer elderly AML patients a better chance at long-term disease control after a stem cell transplant from a partially matched donor.
What could go wrong
This is a small, early-stage study at one center, so results may not apply broadly. The chemotherapy and transplant carry serious risks like infection, graft-versus-host disease, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••